Kbi-098 -

: A prominent small molecule being developed by BioVersys in collaboration with GSK to treat tuberculosis. It is designed to overcome antibiotic resistance and is currently in Phase 2 clinical trials.

The identifier appears to be a combination of terms that relate to several distinct professional and scientific fields. To help clarify which "KBI-098" you are referring to, below is an analysis of how these components are typically used in specialized sectors: 1. Pharmacology and Drug Development

: A major contract development and manufacturing organization (CDMO) that specializes in biologics. While they manage numerous development programs, "KBI-098" does not appear as a standard public designation for their current internal pipeline or client-facing projects. 2. Criminal Justice and Public Safety KBI-098

There is no definitive widely recognized entity, chemical compound, or project known as .

"KBI" is the standard abbreviation for the . : A prominent small molecule being developed by

In the pharmaceutical industry, alphanumeric codes are used to identify investigational drug candidates.

: Geological and forensic studies from 1998 sometimes use similar numbering for "Open File Reports" in the state of Kansas. Drug Research Formulation Lab - KBI Biopharma To help clarify which "KBI-098" you are referring

: The Bureau often publishes annual reports or specific legislative documents that may use numbered designations (e.g., "98" referring to the year 1998 or a specific case file).

Sources:

Bonnie Harris, "'How Many … Were Shot?'" The Spokesman-Review, April 18, 1996 (https://www.spokesman.com); "Life Sentence For Loukaitis," Ibid., October 11, 1997 (https://www.spokesman.com); (William Miller, "'Cold Fury' in Loukaitis Scared Dad," Ibid., September 27, 1996 (https://www.spokesman.com); Lynda V. Mapes, "Loukaitis Delusional, Expert Says Teen Was In a Trance When He Went On Rampage," Ibid., September 10, 1997 (https://www.spokesman.com); Nicholas K. Geranios, The Associated Press, "Moses Lake School Shooter Barry Loukaitis Resentenced to 189 Years," The Seattle Times, April 19, 2007 (https://www.seattletimes.com); Nicholas K. Geranios, The Associated Press, "Barry Loukaitis, Moses Lake School Shooter, Breaks Silence With Apology," Ibid., April 14, 2007 (https://www.seattletimes.com); Peggy Andersen, The Associated Press, "Loukaitis' Mother Says She Told Son of Plan to Kill Herself," Ibid., September 8, 1997 (https://www.seattletimes.com); Alex Tizon, "Scarred By Killings, Moses Lakes Asks: 'What Has This Town Become?'" Ibid., February 23, 1997 (https:www/seattletimes.com); "We All Lost Our Innocence That Day," KREM-TV (Spokane), April 19, 2017, accessed January 30, 2020 through (https://www.infoweb-newsbank.com); "Barry Loukaitis Resentenced," KXLY-TV video, April 19, 2017, accessed January 28, 2020 (https://www.youtube.com/watch?v=KkgMTqAd6XI); "Lessons From Moses Lake," KXLY-TV video, February 27, 2018, accessed January 28, 2020 (https://www.youtube.com/watch?v=QQjl_LZlivo); Terry Loukaitis interview with author, February 2, 2013, notes in possession of Rebecca Morris, Seattle; Jonathan Lane interview with author, notes in possession of Rebeccca Morris, Seattle. 

Licensing: This essay is licensed under a Creative Commons license that encourages reproduction with attribution. Credit should be given to both HistoryLink.org and to the author, and sources must be included with any reproduction. Click the icon for more info. Please note that this Creative Commons license applies to text only, and not to images. For more information regarding individual photos or images, please contact the source noted in the image credit.

Major Support for HistoryLink.org Provided By: The State of Washington | Patsy Bullitt Collins | Paul G. Allen Family Foundation | Museum Of History & Industry | 4Culture (King County Lodging Tax Revenue) | City of Seattle | City of Bellevue | City of Tacoma | King County | The Peach Foundation | Microsoft Corporation, Other Public and Private Sponsors and Visitors Like You